Australia's most trusted
source of pharma news
Posted 29 November 2021 AM
Australia's medicines regulator has green-lighted Bayer's Kerendia to delay progression of kidney disease in patients with chronic kidney disease and type 2 diabetes, close to 11 months after it was accepted for evaluation.
It has approved two doses (10 mg and 20 mg) of Kerendia, a non-steroidal mineralocorticoid receptor antagonist (MRA), in addition to standard of care.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.